SCP & Co. Healthcare Acquisition Company
SHACW
NASDAQ Capital Market0.00
USD
- -
- -
SCP & Co. Healthcare Acquisition Company
SHACW
(NASDAQ Capital Market)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- SCP & CO Healthcare Acquisition Company SCP & CO Healthcare Acquisition Company (SHACW) is a blank check company, or special purpose acquisition company (SPAC), sponsored by SCP & CO, a private equity firm focused on middle-market investments; it seeks to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily targeting healthcare technology platforms and healthcare-related companies in the United States and other developed countries. The company offers no current products or services beyond its SPAC structure, which provides a public listing vehicle for high-growth healthcare technology firms through de-SPAC transactions; its warrants (SHACW) enable holders to purchase Class A ordinary shares at a predetermined exercise price post-business combination, subject to standard SPAC terms. Founded in 2020 and headquartered at 2909 W Bay to Bay Blvd., Suite 300, Tampa, Florida, it operates principally in the financial services sector with a focus on healthcare industry consolidation. The company has not completed an initial business combination since its January 2021 initial public offering, which raised $230 million through 23 million units at $10 each, with shares (SHAC) and warrants (SHACW) separating for trading shortly thereafter; it amended its charter in December 2022 to extend the termination date to December 9, 2022, signaling an early unwind process amid failure to identify a suitable target within the original 24-month deadline from IPO closing. As of late 2025, SHACW warrants continue trading on Nasdaq with minimal volume and significant price depreciation (over 99% one-year return decline), reflecting the absence of a merger and typical post-deadline dilution for non-combined SPACs; no recent partnerships, acquisitions, funding rounds, new launches, or operational expansions have occurred, and the entity maintains a dormant profile characteristic of liquidated or winding-down SPACs without trust redemptions explicitly announced in public filings.